The History of NUVISAN

Founded in 1979 as an independent, family-owned contract research organization (CRO), NUVISAN started with bioanalytical laboratory services and PK/PD studies and later expanded to other areas, such as early discovery, safety testing, clinical trial management, and regulatory support. The company has grown significantly since its founding and has expanded its services and capabilities to meet the changing needs of its clients. In early 2024, ALS took full ownership of NUVISAN, extending our high-quality and personalized solutions to post-commercialisation and to multiple locations worldwide.

2024

In early 2024, ALS took full ownership of NUVISAN by acquiring the remaining 51% shares, integrating NUVISAN into the ALS Group. This strategic acquisition extended our operations to multiple locations worldwide, providing us with access to an extensive global network of knowledge and innovation that will drive our future development.

2021

NUVISAN and ALS Limited signed a strategic partnership to explore new markets. As a strategic investor, ALS Limited (ASX: ALQ) acquired a 49% stake in NUVISAN, aiming to expand its life sciences portfolio. Since the partnership, NUVISAN has become the Centre of Excellence for innovation and technology development for the entire ALS Life Sciences network.

2020

Founding of NUVISAN ICB GmbH and takeover from Bayer of a fully equipped pharmaceutical research unit with 400 workplaces in the field of small-molecule active ingredients.

2019

NUVISAN expands its portfolio to phase II patient trials by acquiring the CRO INAMED in Gauting, near Munich (Germany).

2018

Market entry into chemistry and formulation development. NUVISAN acquires from NESTLÉ SKIN HEALTH parts of the Galderma research activities at Sophia Antipolis (France).

2017

Founding of NUVISAN Inc., a subsidiary of NUVISAN GmbH, in Boston, Massachusetts (USA).

2016

Entry into non-clinical development through the acquisition and integration of the Grafing site (Germany) from long-standing partner Merck KGaA.

2011

Expansion to Waltrop (Germany) by taking over the research institute Essex Pharma from MSD. Integration of large-scale stability programs and services. Expansion into pharmaceutical analysis of hormones, polymers, and large molecules.

2010

Founding as NUVISAN GmbH after the sale of the AAIPharma group of companies to new owners.

2005

The company now trades under the name AAIPharma Deutschland. The company was renamed AAIPharma in the United States at the same time as AAI International.

1997

Takeover by AAI International (Wilmington, NC). The company is a US-based multifunctional contract research organization providing GCP-, GLP- and GMP-related services to the pharmaceutical industry to support early to late product development.

1979

LAB GmbH founded as one of the first German CROs for clinical development in the pharmaceutical industry. In the early clinical phase, the company quickly develops into a full-service provider.